NASDAQ:LQDA - Liquidia Technologies Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.67
  • Forecasted Upside: 637.13 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.08
▼ -0.06 (-1.91%)
1 month | 3 months | 12 months
Get New Liquidia Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LQDA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LQDA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$22.67
▲ +637.13% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Liquidia Technologies in the last 3 months. The average price target is $22.67, with a high forecast of $40.00 and a low forecast of $4.00. The average price target represents a 637.13% upside from the last price of $3.08.
Buy
The current consensus among 3 contributing investment analysts is to buy stock in Liquidia Technologies. This rating has held steady since February 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/2/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/31/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/23/2020

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2020WedbushDowngradeOutperform ➝ Neutral$20.00 ➝ $4.00High
i
Rating by Liana Moussatos at Wedbush
10/15/2020WedbushLower Price TargetOutperform$38.00 ➝ $20.00High
i
Rating by Liana Moussatos at Wedbush
7/7/2020Needham & Company LLCReiterated RatingBuy$24.00Medium
i
7/7/2020WedbushReiterated RatingBuy$38.00Low
i
Rating by Liana Moussatos at Wedbush
6/12/2020WedbushReiterated RatingBuy$41.00High
i
Rating by Liana Moussatos at Wedbush
5/13/2020WedbushReiterated RatingBuy$41.00Medium
i
Rating by Liana Moussatos at Wedbush
5/6/2020CowenReiterated RatingOutperform$40.00Medium
i
5/3/2020WedbushReiterated RatingBuy$41.00Low
i
Rating by Liana Moussatos at Wedbush
4/8/2020WedbushBoost Price TargetOutperform$37.00 ➝ $41.00High
i
Rating by Liana Moussatos at Wedbush
3/11/2020WedbushReiterated RatingBuy$37.00High
i
Rating by Liana Moussatos at Wedbush
3/11/2020Needham & Company LLCReiterated RatingBuy$30.00High
i
1/27/2020WedbushReiterated RatingBuy$37.00Low
i
Rating by Liana Moussatos at Wedbush
12/25/2019WedbushLower Price TargetOutperform$50.00 ➝ $37.00High
i
Rating by Liana Moussatos at Wedbush
11/15/2019WedbushReiterated RatingBuy$50.00Low
i
Rating by Liana Moussatos at Wedbush
6/28/2019WedbushReiterated RatingBuy$50.00High
i
Rating by Liana Moussatos at Wedbush
5/2/2019WedbushReiterated RatingBuyHigh
i
Rating by Liana Moussatos at Wedbush
4/8/2019WedbushReiterated RatingBuy$49.00Medium
i
Rating by Liana Moussatos at Wedbush
3/26/2019WedbushReiterated RatingBuy$48.00 ➝ $49.00Low
i
Rating by Liana Moussatos at Wedbush
3/12/2019WedbushBoost Price TargetOutperform$47.00 ➝ $48.00Low
i
Rating by Liana Moussatos at Wedbush
1/16/2019WedbushReiterated RatingBuy$47.00High
i
Rating by Liana Moussatos at Wedbush
11/28/2018WedbushBoost Price TargetOutperform$28.00 ➝ $47.00Low
i
Rating by Liana Moussatos at Wedbush
11/8/2018Jefferies Financial GroupInitiated CoverageBuy$27.00Medium
i
Rating by Chris Howerton at Jefferies Financial Group Inc.
11/1/2018WedbushBoost Price TargetOutperform ➝ Buy$26.00 ➝ $28.00High
i
Rating by Liana Moussatos at Wedbush
10/31/2018Needham & Company LLCSet Price TargetBuy$32.00Medium
i
Rating by Serge Belanger at Needham & Company LLC
10/31/2018CowenSet Price TargetBuy$40.00High
i
Rating by Ken Cacciatore at Cowen Inc
9/4/2018WedbushInitiated CoverageOutperform ➝ Outperform$26.00Medium
i
Rating by Liana Moussatos at Wedbush
8/20/2018CowenInitiated CoverageOutperform$40.00High
i
8/20/2018Jefferies Financial GroupInitiated CoverageBuy$22.00High
i
8/20/2018Needham & Company LLCInitiated CoverageBuy ➝ Buy$30.00High
i
(Data available from 11/23/2015 forward)
Liquidia Technologies logo
Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC.
Read More

Today's Range

Now: $3.08
$3.03
$3.29

50 Day Range

MA: $4.28
$2.86
$5.79

52 Week Range

Now: $3.08
$2.65
$12.10

Volume

2,315,622 shs

Average Volume

427,051 shs

Market Capitalization

$116.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.51